Anti-invasive activities of experimental chemotherapeutic agents.
We have discussed a number of agents that affect invasion and we have grouped them according to their most probable targets. This strategy is based on the following hypothesis. Invasion is the result of cellular responses to extracellular signals. Candidate signals are components of the extracellular matrix, which are rendered inactive by the flavonoid (+)-catechin (see Section III). Signals are recognized by receptors on the plasma membrane, possibly glycoproteins, that may lose their recognition function through alteration of the oligosaccharide side chains by inhibitors of protein glycosylation (see Section IV) and possibly also by alkyllysophospholipids (see Section V). Synthetic oligopeptides reflecting sequences from cell-binding domains of extracellular matrix molecules are also effective tools for blocking specific receptors (see Section VI). GTP-binding proteins (G proteins) act as signal transducers and can be inactivated by pertussis toxin (see Section VII). An intriguing aspect of both alkyllysophospholipids and pertussis toxin is that they can either inhibit the invasion of constitutively invasive cells or induce invasion of constitutively noninvasive cells. Without doubt, cellular responses implicated in invasion are many-fold. Discussed here are cell motility and directional migration with inhibition through dipyridamole and its analogs and through microtubule inhibitors, respectively (see Section VIII). Alternative hypotheses and alternative strategies for the dissection of the invasion process do exist, and alternative cellular and molecular mechanisms of action may explain the anti-invasive activity of the agents discussed earlier. The latter are mentioned in each section. It is the authors' opinion that the possibilities for exploiting the battery of anti-invasive agents have by no means been exhausted. Introducing researchers to experiments that may lead to an understanding of the mechanisms of invasion and metastasis and to new rationales for cancer treatment has been the purpose of our review.
Mareel
M M
MM
Department of Radiotherapy and Nuclear Medicine, University Hospital, Ghent, Belgium.
De Mets
M
M
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002392:Catechin / Q000627:therapeutic use; D004176:Dipyridamole / Q000627:therapeutic use; D047309:Flavones; D005419:Flavonoids / Q000627:therapeutic use; D005959:Glucosidases / Q000037:antagonists & inhibitors; D006031:Glycosylation; D006801:Humans; D008246:Lysophospholipids / Q000627:therapeutic use; D008361:Mannosidases / Q000037:antagonists & inhibitors; D051379:Mice; D008868:Microtubule Proteins / Q000037:antagonists & inhibitors; D008985:Monensin / Q000627:therapeutic use; D009361:Neoplasm Invasiveness; D009362:Neoplasm Metastasis; D009369:Neoplasms / Q000503:physiopathology / Q000517:prevention & control*; D037342:Pertussis Toxin; D014415:Tunicamycin / Q000627:therapeutic use; D010566:Virulence Factors, Bordetella / Q000627:therapeutic use
D000970:Antineoplastic Agents; D047309:Flavones; D005419:Flavonoids; D008246:Lysophospholipids; D008868:Microtubule Proteins; D010566:Virulence Factors, Bordetella; D014415:Tunicamycin; D004176:Dipyridamole; D002392:Catechin; D008985:Monensin; D037342:Pertussis Toxin; D005959:Glucosidases; D008361:Mannosidases; C059006:tangeretin